Table 3.
Characteristics of bispecific antibodies generated against HCC
| Name/format | MW(kDa) | Affinity (KD) nM | EC50 pM | clone | |||
|---|---|---|---|---|---|---|---|
| Effector (CD3, etc) | Target (GPC3, etc) | ||||||
| Parent clone | Bispecific format | ||||||
| ERY974 (Humanized IgG4 MAb) [42] | 150 | - | - | - | - | - | |
| TriFab [43] | 150 | - | 3.4 | 3.4 | - | GC33 (GPC3) | |
| EpCAM×CD3 BiTE [63] | 54 | - | - | - | 1.42 - 96 | 1H8 (EpCAM) | |
| EpCAM×CD3 BiTE (Solitomab, AMG110, MT110) [113] | 55 | 77 | - | 16–230 | 7.9 | diL2K (CD3) | |
| EpCAM×CD3 (Catumaxomab) [114] | 150 | - | 0.55 | 0.56 | - | Ho-3 (EpCAM), | |
| VEGF×Osteopontin [85] | 200 | - | HuA.4.6.1 (1.55) hu1A12 (9.27) |
HuA.4.6.1 (1.64) hu1A12 (9.43) |
- | HuA.4.6.1 (Bevacizum ab, VEGF), hu1A12 (osteopontin) | |
| (CD3×anti-HCC) DQ-33 [91] | 150 | - | - | - | - | Hepama-6 (anti-HCC) | |
| [92] | CD3×anti- HCC | 100 | - | - | - | - | OKT3 (CD3), L-7- 6 (anti- HCC) |
| CD16×anti- HCC | 100 | - | - | - | - | 3-G-8 (CD16), L- 7-6 (anti- HCC) | |